COX-2 inhibitors

---

• 1.
• Brooks PM. COX-2 inhibitors. Aust Prescriber 2000; 23: 30-32.
• 2.
• Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
• 3.
• Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18 Suppl 28: 6-10.
• 4.
• Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacology 1997; 44: 85-90.
• 5.
• Heerdink ER, Leufkens HG, Herings RMC, et al. NSAIDs associated with increased risk of congestive heart failure in elderly subjects taking diuretics. Arch Intern Med 1998; 158: 1108-1112.
• 6.
• Luong C, Miller A, Barnett J, et al. The structure of human cyclooxygenase-2; conservation and flexibility of the NSAID binding site. Nat Struct Biol 1996; 3: 927-933.
• 7.
• Hawkey CJ. Cox-2 inhibitors. Lancet 1999; 353: 307-314.
• 8.
• Wolfe NM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non steroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-1899.
• 9.
• Karim A, Tolbert DS, Hunt TL, et al. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 2539-2543.
• 10.
• Geis GS. Update on clinical developments with celecoxib, a new specific Cox-2 inhibitor: what can we expect? J Rheumatol 1999; 26 Suppl 56: 31-36.
• 11.
• Bensen WG, Fiechther JJ, McMirren JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095-1105.
• 12.
• Ehrich EW. Effect of specific Cox-2 inhibition in osteoarthritis of the knee: a 6 week double blind placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 2438-2447.
• 13.
• Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol O35 Study Group. Arthritis Rheum 2000; 43: 978-987.
• 14.
• Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastro-intestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-1928.
• 15.
• Emery P, Zeidler H, Kviem TK, et al. Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomised double blind comparison. Lancet 1999; 354: 2106-2111.
• 16.
• Schnitzer T. The safety profile, tolerability and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther 1999; 21: 1688-1702.
• 17.
• Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared to NSAIDs. JAMA 1999; 282: 1929-1933.
• 18.
• Hawkey C, Laine L, Simon T, et al. Comparison of the effects of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placeo on gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43: 370-377.
• 19.
• Komhoff M, Grone H-J, Klein T, et al. Localisation of cyclooxygenase-1 and -2 in adult and fetal human kidney: implications for renal function. Am J Physiol 1997; 272: 460-468.
• 20.
• McAdam BFF, Catella-Lawson IA, Mardini A, et al. Systemic biosynthesis of prostacyclin by cyclo-oxygenase (Cox-2); the human pharmacology of a selective inhibitor of Cox-2. Proc Natl Acad Sci USA 1999; 96: 272-277. [Published erratum appears in Proc Natl Acad Sci USA 1999 May 11; 96: 5890.]
• 21.
• Crofford LJ, Oates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific COX-2 inhibitors: a report of four cases. Arthritis Rheum 2000; 43: 1891-1896.
• 22.
• Richards JS, Fitzpatrick SL, Clemens JW, et al. Ovarian cell differentiation: a cascade of multiple hormones, cellular signals and regulated genes. Rev Prog Hormone Res 1995; 50: 223-254.
• 23.
• Steinbach G, Lynch PM, Phillips RKS. The effect of celecoxib, a cyclo oxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
• 24.
• Peterson WL, Cryer B. Cox-1 sparing NSAIDs -- is the enthusiasm justified? JAMA 1999; 282: 1961-1963.
• 25.
• Schachna L, Ryan PFJ. Cox-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs. Med J Aust 1999; 171: 175-176.